To: Board of Supervisors
From: Anna Roth, Health Services Director
Report Title: Amendment #23-787-1 with Leica Microsystems Inc.
☒Recommendation of the County Administrator ☐ Recommendation of Board Committee
RECOMMENDATIONS:
APPROVE and AUTHORIZE the Health Services Director, or designee, to execute on behalf of the County Contract Amendment #23-787-1 with Leica Microsystems Inc., a corporation, effective February 27, 2024, to amend Contract #23-787, to decrease the minimum monthly purchase commitment required under the Instrument Acquisition Agreement and continue to provide reagent supplies, support and maintenance for tissue sample equipment for the Clinical Laboratory at Contra Costa Regional Medical Center (CCRMC), with no change in the original payment limit of $596,174 or term January 4, 2023 through January 3, 2028.
FISCAL IMPACT:
Approval of this amendment will not result in additional annual expenditures and will be funded as budgeted by the department, 100% by Hospital Enterprise Fund I.
BACKGROUND:
This contract amendment meets the needs of the county by reducing the minimum monthly purchase commitment requirement of the agreement. The Leica Bond Max staining system and associated tissue processor (ASP6025) utilized by the Clinical Laboratory at CCRMC provide an advanced magnetic stirrer technology that optimizes paraffin infiltration and enhances reagent exchange with the tissue cells and cassette printer, minimizing specimen misidentification.
On March 7, 2023, the Board of Supervisors approved Contract #23-787, with Leica Microsystems Inc., an Instrument Acquisition Agreement, in an amount not to exceed $596,174 for the purchase of tissue sample equipment (Bond Max and Tissue Processor ASP6025) and reagent product and supplies for the Clinical Laboratory at CCRMC for the period from January 4, 2023, through January 3, 2028. After executing Contract #23-787, CCRMC began utilizing various other Lecia equipment, which resulted in a reduction in the products used (for the Bond Max) and the minimum monthly purchase commitment requirements of the agreement not being met. As such, the parties have agreed to execute Contract Amendment #23-787-1, amending the Instrument Acquisition Agreement to lower the Purchase Commitment.
Approval of Contract Amendment #23-787-1 will allow the contractor to continue to provide services through January 3, 2028.
CONSEQUENCE OF NEGATIVE ACTION:
If this amendment is not approved, CCRMC can't trade in its existing test equipment that does not allow for rapid testing once a current batch of samples is loaded, creating several workflow challenges and bottlenecks in patient and employee testing.